z-logo
Premium
Pain relief following day case laparoscopic tubal ligation with intra‐peritoneal ropivacaine: a randomised double blind control study
Author(s) -
Dreher JK,
Nemeth D,
Limb R
Publication year - 2000
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.2000.tb01176.x
Subject(s) - ropivacaine , medicine , anesthesia , tubal ligation , saline , nausea , analgesic , laparoscopy , surgery , visual analogue scale , laparoscopic surgery , fentanyl , pain scale , population , environmental health , family planning , research methodology
Summary: The aim of this study was to examine the effectiveness of ropivacaine administered by a simple intraperitoneal technique in relieving pain following laparoscopic application of Filshie clips. Nineteen patients were randomised to receive either ropivacaine (200 mg) or normal saline through the umbilical port following clip application. Using a visual analogue scale women receiving ropivacaine had significantly lower pain scores 2 hours post operatively (0.97 vs 2.03 p < 0.05). The mean total postoperative fentanyl use was also significantly lower on the ropivacaine group (40 μg vs 104 μg p < 0.02). Only 10% (1/10) of the women in the ropivacaine group complained of nausea compared with 44 o (4/9) in the control group. Furthermore, 80% (8/10) of women in the ropivacaine group were either very or totally satisfied with their pain relief. Only 56% (5/9) of the women in the control group were very or totally satisfied with their pain relief. Ropivacaine administered by a simple intraperitoneal technique following laparoscopic sterilisation significantly reduces postoperative pain and parenteral analgesic requirements. It would be reasonable to consider this method as standard practice following laparoscopic tubal ligation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here